Covaxin likely to be only vaccine available for children of 15-18 years

Necessary modifications are being done on the CoWIN portal to register the new category of vaccination

Covaxin
The Drugs Controller General of India (DCGI) granted emergency use authorisation to indigenously-developed Covaxin for children above 12 years with certain conditions on Friday
Press Trust of India New Delhi
2 min read Last Updated : Dec 26 2021 | 10:11 PM IST

Bharat Biotech's Covaxin is likely to be the only COVID-19 vaccine available, for now, for children in the age group of 15-18 years, who will be inoculated from January 3, official sources said.

Also, healthcare and frontline workers and citizens above 60 years of age with comorbidities would be administered the third dose of the same vaccine they had been given before.

Prime Minister Narendra Modi, in a televised address to the nation on Saturday night, announced that vaccination against COVID-19 for children between 15-18 years will start from January 3, while "precaution dose" for healthcare and frontline workers would be administered from January 10.

The decisions came amid rising Covid cases linked to the Omicron variant of the virus.

The precaution dose will also be available for citizens above 60 years of age and with comorbidities on the advice of their doctor from January 10 next year as well, the prime minister had said.

"Bharat Biotech's Covaxin is the only COVID-19 vaccine which will be administered, for now, to children in the age group of 15-18 years who will be inoculated from January 3. The estimated population to be covered in this category is seven to eight crores," an official source said.

The source said that Zydus Cadila's vaccine ZyCoV-D has not yet been introduced in the country's inoculation programme, even for adults, though it had received emergency use authorisation from the drug regulator on August 20, making it the first vaccine that could be administered in the age group of 12-18 years in the country.

The indigenously developed ZyCoV-D is the world's first DNA-based needle-free COVID-19 vaccine.

The gap between the second and third dose of COVID-19 vaccine, which is being termed as "precaution dose", is likely to be nine to 12 months.

Necessary modifications are being done on the CoWIN portal to register the new category of vaccination.

The Drugs Controller General of India (DCGI) granted emergency use authorisation to indigenously-developed Covaxin for children above 12 years with certain conditions on Friday.

More than 61 per cent of India's adult population has received both doses of the vaccine. Similarly, about 90 per cent of the adult population has received the first dose of Covid vaccine.

The cumulative COVID-19 vaccine doses administered in the country has exceeded 141 crore.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronDelta variant of coronavirusCoronavirus VaccineCoronavirus Tests

First Published: Dec 26 2021 | 10:11 PM IST

Next Story